Independent Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts.

Archives: Reports

MARA Rating Company
February 10, 2026

Tecvayli / teclistamab for treating relapsed/refractory multiple myeloma after 3 or more treatments as of January 2026

MARA Rating Company February 10, 2026

Ozureprubart for food Allergy as of January 2026

MARA Rating Company February 10, 2026

Vutrisiran / amvuttra for treating transthyretin amyloidosis with cardiomyopathy as of December 2025

MARA Rating Company February 10, 2026

Durvalumab / imfinzi for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy as of October 2025

MARA Rating Company February 10, 2026

Enfortumab vedotin / padcev for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitable as of September 2025

MARA Rating Company February 10, 2026

Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over as of October 2025

MARA Rating Company February 10, 2026

Glofitamab for treating relapsed or refractory diffuse large B-cell lymphoma as of December 2025

MARA Rating Company February 10, 2026

Guselkumab for treating moderately to severely active ulcerative colitis as of August 2025

MARA Rating Company February 10, 2026

Guselkumab for previously treated moderately to severely active Crohn’s disease as of August 2025

MARA Rating Company February 10, 2026

Raxone / idebenone for treating visual impairment in LeberÕs hereditary optic neuropathy in people 12 years and over as of August 2025

MARA Rating Company February 10, 2026